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Abstract: We report a case of a 67-year-old woman with rheumatoid arthritis with yellow nail syndrome (YNS) that was caused by 
bucillamine. All three signs (yellow fingernails, lymphatic edema, and bronchiectasis) of YNS manifested, with characteristic tim-
ing, first with the nails turning yellow after when bronchiectasis was noticed. We reviewed 10 case reports from Japan and compared 
the periods until the appearance of yellow nails after starting bucillamine treatment, as well as those until lung disease and leg edema 
appeared.
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Introduction
Yellow nail syndrome (YNS) is a rare disease associated 
with pulmonary complaints, mainly bronchiectasis, 
as well as yellow nails and   lymphatic edema. The 
  pathogenesis of YNS remains obscure. However, there 
is a report describing the role of impaired lymphatic 
drainage in the pathogenesis of YNS.1 Bucillamine 
(N-(2-mercapto-2-  methyl-propanoyl)-L-cysteine) is a 
slow-acting   anti-  rheumatic drug, with two S-H bonds 
in its chemical structure.2 An open trial of bucillamine 
treatment (300 mg/day after meals for 16 weeks) was 
conducted  in  11  patients  with  rheumatoid  arthritis 
(RA) who had previous therapeutic failure with gold 
salts and/or D-penicillamine. The results of this trial 
seem to indicate that bucillamine is possibly of value 
as a slow-acting anti-rheumatic drug in some patients 
for whom gold salts or D-penicillamine   therapy has 
failed previously.3 There have been no case reports 
in Japan of bucillamine-induced YNS in RA in which 
pleural effusion appeared before the onset of yellow 
nails. There is a concern regarding the diagnosis of 
YNS  when  respiratory  organ  involvement  appears 
early  without  yellowing  of  the  nails  because  the 
  yellowing of the nails is usually indicative of the YNS 
  diagnosis. When mild pleural effusion occurs while 
administering bucillamine, it is necessary to consider 
the  possibility  of YNS. We  encountered  a  case  in 
which lung involvement preceded the appearance of 
yellow fingernails. This case is discussed here, along 
with a review of the relevant literature.
case Report
A 67-year-old woman was admitted to our hospital 
for  pain  in  the  left  dorsal  region  that  had  been 
  present since July 2004, and an increase in pleural 
effusion  on  X-rays  was  documented  in  September 
2004 (Fig. 1A). She became aware of swelling of both 
hands and elbows in April 1999. Rheumatoid arthritis 
was diagnosed in our hospital in January 2000, and 
she was started on bucillamine at 200 mg per day in 
June. A slight amount of pleural effusion was found 
on her chest X-rays in August 2001 (Fig. 1B), and she   
was hospitalized. The amount of pleural effusion was 
too small to puncture, and nothing else could be done 
except patient follow-up. A chronic productive cough 
appeared in August 2002. Leg edema also became 
marked. Yellow nails were noted in January 2003. No 
further changes were found, and she continued   taking 
the medication until she was hospitalized in 2004. 
During this period, the RA was wholly suppressed by 
bucillamine.
The patient’s temperature was 35.1 °C, blood pres-
sure  132/78  mmHg,  and  pulse  78  bpm.  Her  heart 
sounds  were  normal,  but  her  breath  sounds  were 
decreased on the left. All of her nails were yellow 
(Fig. 2A). Nonpitting edema of both lower limbs was 
noted (Fig. 3A). There was no apparent swelling or 
tenderness of the joints.
X-rays  obtained  at  the  time  of  hospitalization 
revealed  a  diminished  left  costophrenic  angle  that 
had  advanced,  compared  with  earlier  images.  Left 
pleural effusion was documented by a chest CT scan. 
Blood tests revealed no decreased liver functions or 
renal functions (Table 1). Urinary protein was also 
negative.  A  thoracentesis  was  performed,  and  the 
pleural fluid was slightly yellow and hazy because of 
the lymphocyte response. The specific gravity of the 
effusion was 1.037. The Ribalta reaction was positive 
for exudative fluid from the effusion. The patient’s 
rheumatoid factor was negative, and the cytology was 
class 2. Cultures for bacteria, including acid-fast spe-
cies, were negative (Table 2). The patient was diag-
nosed with YNS associated with bucillamine, based 
on her lymphocytic pleural effusion, leg edema, and 
yellow nails. Bucillamine was discontinued. The total 
dose of Bucillamine is 29200 mg. It has not improved 
it though it treated with the Vitamin E. The yellowing 
of her nails (Fig. 2B), pulmonary effusion (Fig. 1C) 
and leg edema persisted (Fig. 3B) in February 2009.
Discussion
The concept of YNS began with a report on a patient 
with yellow nails and lymphatic edema, but eventually 
another  13  cases  were  identified  by  Samman  and 
White in 1964.4 YNS was assumed to be a disease that 
had three signs: refractory pleural effusion, yellow 
fingernails, and lymphatic edema (which was added 
by Emerson in 1966).5 In 1972, Hiller reported that 
YNS was associated not only with pleural effusion 
but also with various other pulmonary complaints, 
including bronchiectasis and pneumonia.6 Although 
yellow nails, lymphatic edema, and pulmonary com-
plaints are the three recognized symptoms of YNS, 
rarely are all three present. However, in 1972, Hiller 
et al reported that the presence of yellow nails and 
one other condition was insufficient for a diagnosis Pulmonary disease as first sign of yellow nail syndrome
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Figure 1. Chest X-rays in August 21, 2001 (A), September 3, 2004 (B), and February 25, 2009 (c). A slight left pleural effusion developed on chest X-rays 
in August 2001, and an increase in chest fluid on X-rays was documented in September 2004. No remarkable change in February 2009.
A B
Figure 2. Appearance of nails. All of the patient’s nails were yellow. July 2004 (A), and February 2010 (B).Isozaki et al
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of YNS.6 In 1979, Mattingly reported three cases that 
suffered concomitant RA.7 In a series of 97 patients 
reviewed  by  Nordkild  in  1986,  yellow  nails  were 
present in 99% of subjects and were the first symptom 
in 37%. Lymphedema was present in 80% and was 
the first symptom in 34%. Respiratory tract involve-
ment was present in 63%; it was the first symptom 
in 29%.8 As a modification of the characteristic nail 
  criterion, a form of YNS can be diagnosed based on 
nail thickening that shows a strong curve transversely 
or longitudinally, color changes (light yellow and light 
green have been observed, usually in all nails) and 
nail detachment. The rate of nail growth diminishes to 
0.1 to 0.25 mm per week or less with this syndrome, 
versus the normal rate of 0.5 to 2.0 mm per week.9
Lymphatic edema might be present in 80% of all 
patients; it can affect the arms and face but is   usually 
seen in the lower limbs. There was a report attrib-
uting yellow nails to abnormalities of the   lymphatic 
Table 2. pleural effusion.
Appearance slightly yellow, hazy
WBC 3800/µl
seg 1.0%
lym 91.0%
mono 8.0%
Tp 5.5 g/dl
LDH 121 IU/l
LDH ratio 0.67
Glu 105 mg/dl
ADA 24.3 IU/l
RF ,0.7 IU/ml
CH50 11.2 U/ml
CeA 2.1 ng/ml
Specific gravity 1.037
Ribalta reaction positive
Bacterial culture Negative
Cytology Class II
Ziehl-Neelsen Dye Negative
Tuberculosis pCR Negative
Table 1. Blood tests.
WBC 6000/µl Tp 8.0 g/dl RF , 7.0 U/ml
neu 69.5% Alb 3.6 g/dl ANA × 320
lym 18.2% Na 143 meq/l Homogeneous
mono 10.0% K 3.5 meq/l Nucleolar
eos 2.0% BUN 21.1 mg/dl IgG 2273 mg/dl
baso 0.3% Cr 0.7 mg/dl IgA 334 mg/dl
RBC 388 × 104/µl GoT 21 IU/l IgM 112 mg/dl
Hb 10.6 g/dl GpT 14 IU/l CH 60.8 U/ml
Ht 32.4% LDH 181 IU/l C3 145 mg/dl
plt 34.4 × 104/µl glu 107 mg/dl C4 20.1 mg/dl
pT 1.09 sec CRp 1.0 mg/dl
ApTT 31.0 sec eSR 74 mm/hr
Fib 495 mg/dl
AB
Figure 3. Bilateral lower limb edema and yellow toenails. Nonpitting edema of both lower limbs was noted. July 2004 (A), and February 2010 (B).Pulmonary disease as first sign of yellow nail syndrome
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vessels.10  Failure  to  form  lymph  or  an  inherent 
  dysfunction of lymphatic vessels would be the mech-
anism underlying lymphatic edema, because lymph 
cannot flow normally when permeability is altered by 
infection, raising the possibility of so-called “lymph 
dropsy”.11
In a recently published case series, pleural biopsy 
specimens  were  available  for  7  of  41  patients.1 
Although  chronic  pleural  inflammation  was  again 
noted,  lymphatic  vessels  appeared  grossly    normal. 
Functional lymphatic disorder, rather than   structural 
disease, is currently favored as the shared   pathogenic 
mechanism for the development of pleural effusions 
and  lymphedema.12  Persistent  cough  and  phlegm 
  production following the onset of the chronic phase 
are  assumed  to  be  the  main  complaints  reflect-
ing    pulmonary  pleural  effusion,  bronchial  tube 
  involvement, and pulmonary irritation. The diagno-
sis of bronchiectasis with chronic bronchitis is based 
on these symptoms. Although, pleural effusion fluid 
is  documented  in  approximately  in  30%  of  cases. 
Although  many  cases  show  bilateral  involvement, 
one-sided disease does occur. There is also a report 
describing organized pneumonia as a cause and the 
efficacy of steroid therapy.13
Other cases with a history of bucillamine   treatment, 
such  as  our  present  patient,  have  been  reported. 
In 2006, Tanaka et al14 reviewed 33 cases in Japan 
treated with disease modifying anti-rheumatic drugs. 
Shortly  thereafter,  28  cases  with  bucillamine  use 
were  reported,  and  the  duration  from  starting  use 
until disease appearance was 17.5 months on average. 
Twenty-three of these cases showed amelioration of 
the disease with discontinuation of the medication 
or  a  dose  reduction.  Yellowing  and  thickening  of 
the  nail  plate  resulting  from  bucillamine  ingestion 
were thought to be caused, in part, by the interrup-
tion of the process of synthesizing keratin because 
bucillamine  disrupts  the  formation  of  a  principal 
ingredient of  the  nail  plate.  In  the  process  of  nail 
plate formation, cysteine, which has an S-H radical, 
becomes cysteine with the formation of an S-S bond 
and is thereby ultimately changed into keratin. It is 
thought that the similarity in the chemical structure 
of bucillamine to cysteine is related to its medicinal 
action, i.e. bucillamine would presumably alter the 
composition of keratin because of its structure being 
similar to that of cysteine (Fig. 4).
As to the disease onset of YNS, the three charac-
teristic signs do not develop simultaneously, and all 
three may fluctuate in severity. Some cases initially 
manifest only yellow nails,4 but others in which yel-
lowing  appear  several  years,  even  decades,  after 
edema  or  lung  disease  have  also  been  reported.5 
We reviewed 10 reports of Japanese cases in which 
signs  of  this    condition  were  followed  temporally 
and compared the periods from starting bucillamine 
until the appearances of yellow nails, pulmonary dis-
ease, and leg edema.14–21 These 10 specific reports 
were  chosen  because  1)  all  three  symptoms  were 
found, and 2) they reported how long it took for the 
three symptoms to appear after taking bucillamine. 
The  average  period  until  the  onset  of  lower  limb 
edema was 13.5 ± 4.6 months, pulmonary disease 
15.6 ± 3.6 months, and yellow nails 11.6 ± 1.6 months. 
There have been no reports of cases with pulmonary 
complaints prior to the appearance of nail yellowing. 
A shift to a chronic respiratory illness, as described by 
Kaneda et al is considered to occur in association with 
infection secondary to lymphatic congestion, trigger-
ing a cycle of recurrent infections with exacerbation 
of pulmonary edema.22 YNS is generally diagnosed 
based on nail thickening, though other symptoms, as 
in our present case, may precede nail manifestations, 
making the diagnosis difficult. When bucillamine is 
prescribed for a patient with RA and lung disease or 
lower edema subsequently appears, YNS should be 
considered in the differential diagnosis.
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Figure 4. Actions of bucillamine on nail plate. It is thought that the simi-
larity in chemical structure of bucillamine to cysteine is related to its 
medicinal action, i.e. bucillamine would   presumably alter the composition 
of keratin because of its structure being similar to that of cysteine.publish with Libertas Academica and 
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